BETASERON 0.3 MG
INTERFERON BETA-1B : 0.3 MG · DIN 02169649 · BAYER INC
Health Canada status: MARKETED
What is BETASERON?
BETASERON 0.3 MG contains INTERFERON BETA-1B : 0.3 MG. It is listed in the Health Canada Drug Product Database under DIN 02169649, held by BAYER INC, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 29-Jan-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BETASERON used for?
BETASERON (interferon beta - 1b) is indicated for: the treatment of patients with a single demyelinating event accompanied by at least two clinically silent lesions typical of multiple sclerosis (MS) on magnetic resonance imaging, to delay progression to definite MS. The reduction of the frequency of clinical exacerbations in ambulatory patients with relapsing - remitting multiple sclerosis. The slowing of progression in disability and the reduction of the frequency of clinical exacerbations in patients with secondary - progressive multiple sclerosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02169649 |
|---|---|
| Brand name | BETASERON |
| Generic / active ingredient | INTERFERON BETA-1B : 0.3 MG |
| Manufacturer | BAYER INC |
| Strength | 0.3 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | L03AB08 INTERFERON BETA-1B |
| AHFS class | 92:20.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jan-2008 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02169649 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2169649 |
| Brand name | BETASERON |
| Active ingredient / INN | INTERFERON BETA-1B : 0.3 MG |
| ATC code | L03AB08 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L03 |
| AHFS class | 92:20.00 |
| Health Canada schedule | Schedule D |
| Biosimilar biologic | No |
| Market authorization holder | BAYER INC |
How is it stored and handled?
null
How is it supplied?
15 single-use carton packs, each containing: 1 vial of medication, 1 prefilled diluent syringe (1.2 mL Sodium Chloride 0.54% solution), and 1 vial adapter with attached 30 gauge, ½" needle.
Which pack is which?
| Strength on the label | 0.3 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | SUBCUTANEOUS |
| Packaging as described in the monograph | 15 single-use carton packs, each containing: 1 vial of medication, 1 prefilled diluent syringe (1.2 mL Sodium Chloride 0.54% solution), and 1 vial adapter with attached 30 gauge, ½" needle. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code L03AB08 INTERFERON BETA-1B. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EXTAVIA | 0.3 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02337819 |
Who else supplies INTERFERON BETA-1B worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INTERFERON BETA-1B appears in 84 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.